Collaborations And PartnershipsThe recent collaborations are expected to test Rezlidhia in additional IDH1-mutant cancers, potentially driving future revenue growth.
Financial PerformanceRigel announced 4Q23 and 2023 full year financial results, posting EPS of $0.00 and ($0.14), respectively, exceeding analysts’ estimates.
Product SalesSales of Rezlidhia for IDH1m r/r AML increased by ~29% QoQ to $4.9M, which was above the analyst's expectations.